Sharp Therapeutics postpones annual shareholder meeting to July 21 from June 30

  • Sharp Therapeutics postponed its annual shareholder meeting to July 21, 2026 from June 30, 2026.
  • The revised agenda adds a vote to re-approve the company’s stock option plan, prompting amended proxy materials.
  • Prior voting instructions are void; shareholders must recast votes, with proxies due by 10:00 a.m. Toronto time on July 17, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sharp Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606301700NEWSFILECNPR____20260630_303542_1) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.